With a PhD in chemistry and "a general passion" for the work, J. David Rozzell started making enzymes for drug companies seven years ago with a handful of employees in his Pasadena lab. Today, he is president and CEO of BioCatalytics, a private company that has 25 employees and generates enough cash to pay for itself. "From the first year, we were break-even or better," says Rozzell. "we were funded by our operations – by the revenue we could generate. Then our funding came from sponsored research agreements with big drug companies, product sales, and federal SBIR [Small Business Innovation Research] grants."